“These findings suggest that social factors such as marital status may serve as important markers of cancer risk at the population level,” stated Paulo Pinheiro, M.D., Ph.D., reflecting on a recent study that has uncovered troubling trends in cancer rates among unmarried adults.
The study analyzed over 4 million cancer cases across 12 states from 2015 to 2022, revealing that unmarried adults, especially men, have significantly higher rates of several cancers. Notably, adult men who were never married had approximately five times the rate of anal cancer compared to their married counterparts. Similarly, adult women who were never married had nearly three times the rate of cervical cancer compared to those who were or had been married.
Frank Penedo, Ph.D., emphasized the implications of these findings, saying, “It’s a clear and powerful signal that some individuals are at a greater risk.” This stark contrast in cancer rates raises questions about the underlying social determinants of health, particularly how marital status may influence cancer risk and outcomes.
In addition to the alarming statistics regarding unmarried adults, the study also highlighted disparities among different demographic groups. Black men who were never married exhibited the highest overall cancer rates, while married Black men had lower cancer rates than married white men. This suggests that social and racial factors intertwine, further complicating the landscape of cancer risk.
On a different front, advancements in cancer treatment are also making headlines. Proton therapy, a cutting-edge treatment option, allows oncologists to deliver cancer-killing radiation precisely to tumors while minimizing damage to surrounding healthy tissues. Billy Loo, MD, PhD, remarked, “Proton therapy helps us balance that equation by making radiotherapy more precise,” indicating its potential to improve treatment outcomes for patients.
Stanford Medicine recently opened a new proton therapy facility on April 7, 2026, aiming to provide patients with access to this innovative treatment. Proton therapy is particularly effective for tumors located in sensitive areas such as the brain, spine, head and neck, lungs, liver, and prostate. However, as Susan Hiniker, MD, cautioned, “Proton therapy isn’t the right choice for every cancer, however,” highlighting the need for personalized treatment plans.
In clinical trials, patients with metastatic pancreatic cancer who received the daily pill daraxonrasib lived a median of 13.2 months, nearly twice as long as those who received traditional chemotherapy. This promising development underscores the ongoing research efforts to improve cancer treatment and patient survival rates.
As the medical community continues to explore the links between social factors and cancer risk, the findings from this study serve as a crucial reminder of the importance of addressing health disparities. The next steps will likely involve further research into how marital status and other social determinants can be leveraged to improve cancer prevention and treatment strategies.
